PCRX Q2 2025 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$181M+1.7% YoY

Gross Profit

$140M77.4% margin

Operating Income

$8M4.7% margin

Net Income

-$5M-2.7% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$9M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$779M

Stockholders' Equity

$758M

Cash & Equivalents

$300M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$178M	+1.7%
Gross Profit	$140M	$134M	+4.8%
Operating Income	$8M	$28M	-69.9%
Net Income	-$5M	$19M	-125.7%

Revenue Segments

Product

$180M51%

EXPAREL

$143M40%

ZILRETTA

$31M9%

Bupivacaine Liposome Injectable Suspension

$508,0000%